Background
==========

MHC (Major Histocompatibility Complex) is a large gene family with an important role in the immune system, autoimmunity, and reproduction. MHC molecules assume roles in the presentation of peptides, including self and non-self (antigenic) on their surface to T-cells. T-cells recognize antigenic peptides and trigger a cascade of events which leads to the destruction of pathogens and infected cells. Since MHCs have a key role in immune response, they are critical in many diseases, and can be used for controlling specific immunological processes by creating peptides to bind to specific MHC alleles. This binding affinity to specific peptides may be exploited for creating peptide vaccines for emerging pathogens \[[@B1]\], suppressing specific alleles in organ transplants \[[@B2],[@B3]\], and many other possible areas in immunotherapy.

MHC class I molecules bind short peptides, whose N- and C-terminal ends are anchored into the pockets located at the ends of the peptide binding groove \[[@B4]\]. While the majority of the peptides are of length 9, longer peptides can be accommodated by the bulging of their central portion \[[@B5],[@B6]\], resulting in binding peptides of length 8 to 15 \[[@B7]\]. Peptides binding to class II proteins are not constrained in size \[[@B8],[@B9]\] and can vary from 11 to 30 amino acids long \[[@B10]\]. The peptide binding groove in the MHC class II molecules is open at both ends, which enables binding of peptides with relatively longer length. Though the \"core\" nine residues long segment contributes the most to the recognition of the peptide, the flanking regions are also important for the specificity of the peptide to the class II allele \[[@B11],[@B12]\]. MHC molecules bind peptides with high promiscuity; it is estimated that each HLA (human leukocyte antigen system) protein can bind between 1000 and 10,000 peptides for class I allotypes \[[@B13]\] and more than 2000 peptides for class II allotypes \[[@B14]\]. Thus, the large number of possible structures makes it unfeasible to find peptides that will bind to a specific allele using solely an experimental approach.

Computational methods for prediction of the binding affinity of a peptide to an MHC allele are based on three main artificial learning systems: statistical, structural, and neural methods \[[@B13],[@B15],[@B16]\]. The combination of these models is also common \[[@B17]\]. Computational approaches available for predicting MHC binding peptides from amino acid sequences include: (i) Motif-based methods such as methods that use a position weight matrix (PWM) to model a gapless multiple sequence alignment of MHC binding peptides \[[@B4]-[@B8]\], and a statistical approach based on Hidden Markov Models (HMMs) \[[@B9],[@B10]\]; (ii) Machine learning methods based on Artificial Neural Networks (ANN) \[[@B6],[@B11]-[@B13]\] and Support Vector Machines (SVMs) \[[@B14]-[@B17]\]; (iii) Semi-supervised machine learning methods \[[@B18],[@B19]\]. Existing methods are reviewed in detail in \[[@B18],[@B19]\].

The formation of bulges and loops may allow peptides that are shorter or longer than 9 amino acids to bind to class I alleles. This length variance shifts the positions of amino acids in anchor locations, causing position-specific scoring matrices or other position-dependent methods to fail. Most existing methods enforce a length constraint of 9 peptides for class I prediction. ANN, quantitative matrices and similar methods require the peptides to be of the same length, with appropriate peptides aligned in the same location. Peptides of different lengths are either ignored or grouped into separate datasets by their length. This step may not always be feasible if the data is limited, especially for short and variable peptides.

Unlike MHC class I prediction methods, most of the MHC class II prediction methods can utilize peptides of variable length. However, the prediction strategy requires the determination of the core 9-mer region of the peptide. This core segment is assumed to be fixed-length and the possibility of longer binding core sequences is disregarded. Although peptides bind to MHC class II alleles mostly by the anchor residues, the interactions of the flanking regions may be important for specificity and therefore have to be taken into account \[[@B20]\].

In order to overcome these obstacles, we suggest a method using partial periodic pattern mining, which does not require the peptides to be of same length or the anchor positions to be specific. We propose a novel method for extracting the motifs on peptides with variable lengths by finding partial motifs in sequence data. Our method, called MHC-PPM, may capture aforementioned variations in peptides, without filtering or pre-processing the shorter/longer peptides or treating them as separate datasets. Additionally, the information in the flanking regions of the core 9-mers is taken into account without any information loss that may have arisen due to length constraints.

Methods
=======

Dataset
-------

We used 28 different alleles from the Immune Epitope Database (IEDB) benchmark dataset by Peters et al. \[[@B21],[@B22]\] for MHC class I prediction (total of 36,829 peptides). For MHC class II, we used two benchmark sets from Wang et al., 16 alleles containing 10,017 peptides \[[@B19]\] (referred to as Wang2008), and 26 alleles containing 44,541 peptides \[[@B23]\] (referred to as Wang2010). Wang2010 contains data from several different human alleles, including HLA DR, DP and DQ. Wang2010 data also contains a similarity reduced subset (SR), where sequence similarity is minimized in order to reduce the overlap between cross-validation folds. In Peters and Wang2010 datasets, the same cross-validation folds are used for comparison to the benchmark values. 10-fold cross-validation was used in Wang2008 dataset.

The peptides from these alleles are assigned into positive and negative classes by the IC~50~= 500 nM cut-off. Unlike other MHC prediction methods, no filtering was made with regard to length during the motif mining and prediction steps.

Motif mining
------------

### i-) Apriori method

Our motif mining method is based on the apriori algorithm used in frequent association rule discovery \[[@B24]\]. An \"itemset\" is defined as a set of items or events that co-occur frequently. The Apriori algorithm uses the principle that all subsets of a frequent itemset must also be frequent. Accordingly, the algorithm has a bottom-up approach where the shorter frequent itemsets are extended to create longer candidates, which are then filtered by frequency of occurrence \[[@B24]-[@B26]\]. This iterative extension process continues until no frequent itemsets of a certain length can be found.

Due to the context difference, the formal statement of the problem in the Apriori algorithm \[[@B26]\] is slightly modified. Let *I*= {*i*1, *i*2*,\..., im*} be an alphabet of items called *events*(amino acids in our case). Let *D*be a set of sequences, where each sequence *S*is an ordered set of items such that *S*⊆ *I*. A sequence *S*contains *itemsetX*, an ordered set of some items in *I*, if *X*⊆ *S*. A rule is of the form, where *X*⊂ *I*, *Y*⊂ *I*. With temporal information, {*X*→*Y*} also implies that the events in X occur before Y in a sequence S containing the rule.

The ratio of the sequences containing the association rule to all of the sequences is called the support of the rule. The ratio of the sequences containing a new rule created by the combination of two rules to the sequences containing the previous rule is called the confidence. That is,

$$Conf\left( X\rightarrow Y \right) = \frac{Support\left( {X \cup Y} \right)}{Support\left( X \right)}$$

Our motif mining method (MHC-PPM) is similar to temporal event mining in time-related databases \[[@B27]\]. In general, the partial periodic pattern mining algorithms for time series data will attempt to find frequently co-occurring events, or causality relationships between them. These methods try to capture the patterns which occur in an order which is not necessarily a consecutive one. In the domain of protein motifs, the amino acids become the \"events\" and the causality/future prediction aspects become the motifs that are sought \[[@B28]\].

In the proposed approach, each sequence is taken as a separate time series, with many parallel events occurring at the same time, with each event related only to the sequence upon which it is found. In these time series, if an event happens frequently after another one within a given time window, this frequent occurrenceis considered an episode of events, a motif. To exploit the apriori principle for performance, the motifs begin from length 1. A longer motif including a specific amino acid will have support less than or equal to the support of that amino acid. Hence, if an amino acid is infrequent, any motif that includes that amino acid will also be infrequent. Thus, iteratively L~N~(frequent itemset of size N) is created from filtering of C~N~, candidate itemset of size N by *C~N~*= *L*~*N*-1~→*L*~1~.

First L~1,~the frequent itemsets of size 1 (i.e. amino acids) are found. The first step is straightforward: only the amino acids within the sequences are counted, and if an amino acid\'s frequency (support of the rule) is below the given threshold, the amino acid is filtered out.

Then the candidate set of size 2, C~2~is created from the amino acids by L~1~→L~1~, that is, the combination of any two frequent itemsets of size 1. For example, if all of the 20 amino acids were frequent, we would have 400 candidate rules at C~2~for the given parameters. Those candidate rules would then be filtered according to the preset minimum support values, yielding L~2~. Only a handful of those 400 rules would be frequent in the data. An example rule of size 2 would be {L→V}, which represents Leucine followed by Valine in a window specified by parameters. The support of this candidate rule will be the ratio of occurrence of L→V to all of the sequences, and the confidence of the rule would be the ratio of occurrence of L→V to all of the sequences that contain \"L\" at some point. In other words, confidence would be the conditional probability of seeing Valine in the window, given that we observed a Leucine.

To account for the position variations in the alleles, a specific window should be defined. If an amino acid X is followed by Y after at least *MinS*and at most *MaxS*positions, then the rule {X → Y} is present in that sequence. If these amino acids co-occur within this window by this specific order at least *minimum support*times, then it is considered frequent.

In the motif mining context, the frequent rules are not simply association rules as in a shopping basket analysis; items also have a temporal value, which is used for relations such as \"before\" and \"after\" (\"simultaneously\" is not used in protein motifs since at each time point, that is a specific position in the sequence, only one amino acid can occur). The episode A→B then becomes, \"whenever the events in the rule A occur in a given sequence, event B is likely to occur within *n*to *m*positions after A, with P(A → B) as *p (support)*and P(B \| A) as *c (confidence)*\".

There are two parameters, the slack length (*s*), which is the length after an event within which we do not look for a rule, and the window size (*w*), in which the consequent event may occur. Thus, *MinS*= *s*and *MaxS*= *s*+ *w*- 1, and the rule is given as A→B (p, c) for parameters (s, w). An example motif mining step is given in Figure [1](#F1){ref-type="fig"} and Additional File [1](#S1){ref-type="supplementary-material"} the pseudocode of the algorithm is given in Figure [2](#F2){ref-type="fig"}.

![**An example of the temporal rule mining process**. **a-)**Schematic representation of the sliding windows approach on a sample set of sequences binding to MHC class I allele HLA A\*0201. The windows are shifted with the given s and w values until all sequences are covered. The resulting rules are then filtered by their support. This process is repeated for all s values from -8 to -1 and 1 to 8. **b-)**Representation of the L→V rule captured with the parameters s = 6 and w = 3. For HLA A\*0201, Leucine in 2^nd^position and Valine around 9^th^position is a well-known binding motif \[[@B40]\]. Although this motif is present in 6 of the 7 sequences (support of 0.86), it is unlikely to be captured by position specific methods due to length variance and positional shifts.](1471-2105-14-S2-S13-1){#F1}

![**Pseudocode of the temporal apriori motif mining algorithm**.](1471-2105-14-S2-S13-2){#F2}

In our simulations, we used a window size of 1 to 3 and slack length of -8 to 8, producing different rulesets. Negative slack values are taken by reversing the input sequences and applying the algorithm with the absolute value of the slack.

For *s*= 1 and *s*= -1, the rules that consist of consecutive/nearby amino acids were mined whereas for the larger values of s, the motifs consisting of amino acids at separate ends of the peptide were found. Since the anchor positions of MHC motifs may be different, different slack lengths are needed to mine them all.

### ii-) Position dependent 1-rules

With the addition of position information, single amino acids can be employed as rules for anchors. When mining 1-rules, the position information is kept along with the window size. Thus, an example rule with window size of 2 may be {L, between positions 3-4 (support: p, confidence: c)}. This rule will be counted as present in a peptide which includes a Leucine between the positions 3 and 4.

### iii-) Recursive rule mining on training set

In the rule mining process, the rules are mined for different slack lengths and finally 1-rules are added to the collection of rules. Following the rule mining process, all of the peptides in the training set are scored by the rules according to the Support-based prediction described below. After scoring every peptide in the training data, any peptide scoring below a predefined threshold is separated. Those separated peptides that are not sufficiently explained by the motifs are fed into the motif mining recursively.

This process can be thought of as mining rules for different clusters of sequences; the first iteration will try to capture the motifs for the cluster with the most sequences. After that, sequences that scored poorly will be used in motif mining again in the second iteration, and since the data is only a subset of the previous iteration, the limit for reaching minimum support will be lower. This process is repeated until the number of peptides that score lower than the threshold is below a predefined limit, until no more improvement can be gained by dividing the dataset or until a hard limit on iteration is reached. The supports for the newly mined rules are updated to reflect the support in all of the data, not the subset. An overall view of the recursive rule mining steps are given in Figure [3](#F3){ref-type="fig"}.

![**Overall flow of the recursive rule mining step**.](1471-2105-14-S2-S13-3){#F3}

The recursive rule mining has advantages compared to setting the minimum support and confidence threshold to lower values and mining the rules in one pass. If the rules are mined in one pass with a very low support threshold, a greater number of rules will be found. Unless those rules are significant, the signal-to-noise ratio will decrease. By using a greater initial support value and progressively decreasing it on only a subset of data, the number of possible rules is reduced; if the first pass can capture motifs that are present in 70% of all sequences, we will only mine rules for explaining the remaining 30%, not the entire dataset. Hence, we end up with a lower number of more significant rules that explain the majority of the data.

Prediction
----------

Before prediction, rules from both the binding and non-binding sequences are mined separately. During classification of an unknown peptide, the peptide is scored independently by both the binding and non-binding rules. The simplest classification method is the direct comparison of the scores for binding/non-binding rules. To calculate the scores, the support values of the rules that occur in the given peptide are summed for both classes. The peptide is predicted to belong to the class with a higher score. This naïve approach is called Support-based prediction and only used during the recursive rule mining step.

The presence of one significant negative motif can turn an otherwise strongly binding peptide to a non-binding one. For example, in the allele H-2Kd, charged or bulky amino acids inhibit binding when they are present at the 5^th^position, even though the binding motif may also be present \[[@B29]\]. In a naïve prediction method, if the binding motifs are strong enough, the large number of binder rules will overpower the single negative motif, causing a false positive. Consequently, there is need for a way to predict these enhancing/inhibiting effects of the rules. Non-linear classification methods that intrinsically find the discriminant function on the feature space would fare better in such data.

For SVR-based prediction, motif mining is employed on the training data as described above. Using the motifs, a dataset is built by creating a binary matrix, where each row is a peptide and each column (feature) represents a motif. A cell has the value 1 if the peptide corresponding to that row includes the motif, otherwise 0. As additional columns, the sums of support and confidence scores for both the positive and negative classes are given. This data matrix is built for both the training and the test sets. Then, an SVR is trained on the training set, and the binding affinities of the peptides in the test set are predicted by the support vectors. The resulting binding affinity values can be converted into a binary class using an IC~50~threshold where a binary class is required, such as feature selection methods or AUC calculation.

Since the training set is used in all of the rule mining, SVR training and parameter optimization steps, the prediction of the test set does not include any bias and represents the actual predictive performance of MHC-PPM.

The overall view of the prediction workflow can be seen in Figure [4](#F4){ref-type="fig"}.

![**Overview of the experimentation process**.](1471-2105-14-S2-S13-4){#F4}

Results and conclusions
=======================

MHC class I
-----------

The prediction results of the proposed method are given in Table [1](#T1){ref-type="table"} along with the benchmark results for comparison \[[@B22]\]. The given values represent the area under the ROC curve (AUC) for the 5-fold cross validation using the same fold splits in the benchmark set.

###### 

Results of MHC-PPM in class I predictions in Peters dataset \[[@B22]\].

                     Allele                \# Peptides   ANN    ARB                SMM     MHC-PPM            
  ------------------ --------------------- ------------- ------ ------------------ ------- ------------------ ------------------
  9-mers + 10-mers   HLA-A\*0201           3089          1316   \-                 0.919   **[0.939]{.ul}**   0.931
                     HLA-A\*0202           1447          1056   \-                 0.851   **[0.879]{.ul}**   0.871
                     HLA-A\*0203           1443          1055   \-                 0.838   0.878              **[0.882]{.ul}**
                     HLA-A\*0301           2094          1082   \-                 0.883   **[0.915]{.ul}**   0.911
                     HLA-A\*0206           1437          1054   \-                 0.849   **[0.890]{.ul}**   0.885
                     HLA-A\*1101           1985          1093   \-                 0.897   0.932              **[0.937]{.ul}**
                     HLA-A\*2402           197           78     \-                 0.722   0.809              **[0.833]{.ul}**
                     HLA-A\*3101           1869          1057   \-                 0.881   **[0.903]{.ul}**   0.878
                     HLA-A\*3301           1140          1055   \-                 0.866   **[0.888]{.ul}**   0.863
                     HLA-A\*6801           1141          1055   \-                 0.827   **[0.874]{.ul}**   0.864
                     HLA-B\*0702           1262          205    \-                 0.925   0.952              **[0.954]{.ul}**
                     HLA-B\*3501           736           177    \-                 0.833   **[0.886]{.ul}**   0.866
                     HLA-B\*5101           244           177    \-                 0.782   0.875              **[0.886]{.ul}**
                     HLA-B\*5301           254           177    \-                 0.758   **[0.854]{.ul}**   0.847
                                                                                                              
  9-mers             HLA-A\*0101           1157          \-     **[0.982]{.ul}**   0.964   0.980              0.963
                     HLA-A\*2601           672           \-     **[0.956]{.ul}**   0.907   0.931              0.901
                     HLA-A\*2902           160           \-     **[0.935]{.ul}**   0.755   0.911              0.907
                     HLA-A\*6802           1434          \-     **[0.899]{.ul}**   0.865   0.898              0.867
                     HLA-B\*0801           708           \-     **[0.955]{.ul}**   0.936   0.943              0.926
                     HLA-B\*1501           978           \-     0.941              0.900   **[0.952]{.ul}**   0.922
                     HLA-B\*1801           118           \-     0.838              0.573   0.853              **[0.906]{.ul}**
                     HLA-B\*2705           969           \-     0.938              0.915   **[0.940]{.ul}**   0.938
                     HLA-B\*4002           118           \-     0.754              0.541   0.842              **[0.891]{.ul}**
                     HLA-B\*4402           119           \-     0.778              0.533   0.740              **[0.891]{.ul}**
                     HLA-B\*4403           119           \-     0.763              0.461   0.770              **[0.847]{.ul}**
                     HLA-B\*5401           255           \-     0.903              0.847   **[0.921]{.ul}**   0.883
                     HLA-B\*5701           59            \-     0.826              0.428   0.871              **[0.929]{.ul}**
                     HLA-B\*5801           988           \-     0.961              0.889   **[0.964]{.ul}**   0.944
                                                                                                              
                     **Average (All)**                          0.888              0.798   0.893              **[0.897]{.ul}**
                     **Average (9mers)**                        0.888              0.751   0.894              **[0.908]{.ul}**
                     **Weighted Avg**                           **[0.932]{.ul}**   0.872   0.910              0.901

The best-performing method for each allele is underlined. The given AUC values for ARB and SMM are the weighted averages of the AUC values for 9-mers and 10-mers based on the given peptide counts for a specific allele. The alleles in the bottom part of the table were only trained & tested in 9-mers and are directly comparable.

Note that for some alleles (given in the top part of Table [1](#T1){ref-type="table"}) the AUC values between the methods are not directly comparable because filtering of the data differs based on the prediction method in use. ANN \[[@B30]\] use only the 9-mers, the peptides of other lengths are filtered out. SMM uses 9-mers and 10-mers, but trained and tested independently (i.e. 9-mers belonging to an allele and 10-mers belonging to the same allele are taken as separate sets and are fed to different predictors). As stated, our method uses peptides of all lengths in the same classifier, without any filtering or separation. For the comparison in Table [1](#T1){ref-type="table"} the weighted average of AUC values using the 9-mer and 10-mer peptide counts are given for SMM \[[@B31]\] and ARB \[[@B32]\]. The results are directly comparable for alleles with only 9-mers.

Although superior in 9-mers, the main limitation of ANN is the need for the peptides to be of fixed length. The same constraint is also present in SMM and is overcome by using separate datasets for 9-mers and 10-mers. The main advantage of MHC-PPM is giving comparable and superior results to other methods without enforcing any constraints on peptide length. This flexible approach allows the use of information from all of the available data. Peptides that do not have enough representation in the dataset to train a separate classifier (e.g. 8 or 11 amino acids long) can still be predicted using the data from the 9 and 10-mers.

MHC class II
------------

Results for Wang2008 \[[@B19]\] and Wang2010 \[[@B23]\] datasets are given in Table [2](#T2){ref-type="table"} and Table [3](#T3){ref-type="table"} respectively. Each method in the Table [3](#T3){ref-type="table"} has results for both all of the dataset (ALL) and a similarity-reduced version of the dataset (SR), used to decrease the sequence similarity between data folds.

###### 

Results of MHC-PPM in class II predictions in Wang2008 dataset \[[@B19]\].

  Allele           \#     RANKPEP   ARB                PROPRED            SMM-align   MHCMIR             MHC-PPM
  ---------------- ------ --------- ------------------ ------------------ ----------- ------------------ ------------------
  HLA-DRB1\*0101   3882   0.700     0.760              0.740              0.770       0.810              **[0.878]{.ul}**
  HLA-DRB1\*0301   502    0.670     0.660              0.650              0.690       0.640              **[0.712]{.ul}**
  HLA-DRB1\*0401   512    0.630     0.670              0.690              0.680       **[0.730]{.ul}**   0.666
  HLA-DRB1\*0404   449    0.660     0.720              0.790              0.750       0.730              **[0.792]{.ul}**
  HLA-DRB1\*0405   457    0.620     0.670              **[0.750]{.ul}**   0.690       0.730              0.734
  HLA-DRB1\*0701   505    0.580     0.690              0.780              0.780       0.830              **[0.893]{.ul}**
  HLA-DRB1\*0802   245    \-        0.740              0.770              0.750       0.740              **[0.827]{.ul}**
  HLA-DRB1\*0901   412    0.610     0.620              \-                 0.660       0.620              **[0.666]{.ul}**
  HLA-DRB1\*1101   520    0.700     0.730              0.800              0.810       0.810              **[0.817]{.ul}**
  HLA-DRB1\*1302   289    0.520     **[0.790]{.ul}**   0.580              0.690       0.720              0.679
  HLA-DRB1\*1501   520    0.620     0.700              0.720              0.740       0.730              **[0.759]{.ul}**
  HLA-DRB3\*0101   420    \-        0.590              \-                 0.680       \-                 **[0.712]{.ul}**
  HLA-DRB4\*0101   245    0.650     0.740              \-                 0.710       0.760              **[0.829]{.ul}**
  HLA-DRB5\*0101   520    0.730     0.700              0.790              0.750       0.710              **[0.845]{.ul}**
  H-2 IAb          500    0.740     **[0.800]{.ul}**   \-                 0.750       0.690              0.786
  H-2 IEd          39     0.830     \-                 \-                 \-          \-                 **[0.867]{.ul}**
                                                                                                         
  Average                 0.661     0.705              0.733              0.727       0.732              **[0.779]{.ul}**
  Weighted Avg            0.671     0.722              0.738              0.743       0.760              **[0.780]{.ul}**

The (\#) column gives the total number of peptides for the given allele. The best-performing method for each allele is underlined.

###### 

Results of MHC-PPM in MHC class II predictions in Wang2010 dataset \[[@B23]\].

  Allele                      \# Peptides   ARB    SMM-align   NN-align   MHC-PPM                                                         
  --------------------------- ------------- ------ ----------- ---------- --------- -------------- ----------- -------------- ----------- --------------
  HLA-DPA1\*0103-DPB1\*0201   1404          603    0.823       0.745      0.921     0.767          **0.943**   [0.793]{.ul}   0.931       0.772
  HLA-DPA1\*01-DPB1\*0401     1337          540    0.847       0.746      0.930     0.767          **0.947**   [0.802]{.ul}   0.935       0.751
  HLA-DPA1\*0201-DPB1\*0101   1399          604    0.824       0.743      0.909     0.786          **0.944**   [0.818]{.ul}   0.938       0.806
  HLA-DPA1\*0201-DPB1\*0501   1410          586    0.859       0.709      0.923     0.728          **0.956**   [0.787]{.ul}   0.948       0.773
  HLA-DPA1\*0301-DPB1\*0402   1407          602    0.821       0.771      0.932     0.818          **0.949**   [0.828]{.ul}   0.935       0.815
  HLA-DQA1\*0101-DQB1\*0501   1739          584    0.871       0.741      0.930     0.783          0.945       0.805          **0.949**   [0.754]{.ul}
  HLA-DQA1\*0102-DQB1\*0602   1629          593    0.777       0.708      0.838     0.734          **0.880**   [0.762]{.ul}   0.842       0.730
  HLA-DQA1\*0301-DQB1\*0302   1719          596    0.748       0.637      0.807     0.663          **0.851**   0.693          0.845       [0.709]{.ul}
  HLA-DQA1\*0401-DQB1\*0402   1701          585    0.845       0.643      0.896     0.761          **0.922**   0.742          0.920       [0.778]{.ul}
  HLA-DQA1\*0501-DQB1\*0201   1658          589    0.855       0.700      0.901     0.736          **0.932**   [0.777]{.ul}   0.919       0.766
  HLA-DQA1\*0501-DQB1\*0301   1689          602    0.844       0.756      0.910     0.801          **0.927**   [0.811]{.ul}   0.915       0.771
  HLA-DRB1\*0101              6427          3504   0.770       0.710      0.798     0.756          **0.843**   [0.763]{.ul}   0.821       0.758
  HLA-DRB1\*0301              1715          1136   0.753       0.728      0.852     0.808          **0.887**   [0.829]{.ul}   0.828       0.747
  HLA-DRB1\*0401              1769          1221   0.731       0.668      0.781     0.721          **0.813**   [0.734]{.ul}   0.763       0.711
  HLA-DRB1\*0404              577           474    0.707       0.681      0.816     0.789          0.823       0.803          **0.885**   [0.717]{.ul}
  HLA-DRB1\*0405              1582          1049   0.771       0.716      0.822     0.767          **0.870**   [0.794]{.ul}   0.831       0.734
  HLA-DRB1\*0701              1745          1175   0.767       0.736      0.834     0.796          **0.869**   [0.811]{.ul}   0.846       0.804
  HLA-DRB1\*0802              1520          1017   0.702       0.649      0.741     0.689          **0.796**   [0.698]{.ul}   0.752       0.687
  HLA-DRB1\*0901              1520          1042   0.747       0.654      0.765     0.696          **0.810**   [0.713]{.ul}   0.762       0.671
  HLA-DRB1\*1101              1794          1204   0.800       0.777      0.864     0.829          **0.900**   [0.847]{.ul}   0.858       0.811
  HLA-DRB1\*1302              1580          1070   0.727       0.667      0.797     [0.754]{.ul}   **0.814**   0.732          0.768       0.717
  HLA-DRB1\*1501              1769          1171   0.763       0.696      0.796     0.741          **0.852**   [0.756]{.ul}   0.813       0.745
  HLA-DRB3\*0101              1501          987    0.709       0.678      0.819     0.780          **0.856**   [0.798]{.ul}   0.782       0.718
  HLA-DRB4\*0101              1521          1011   0.785       0.747      0.816     0.762          **0.870**   [0.789]{.ul}   0.860       0.772
  HLA-DRB5\*0101              1769          1198   0.760       0.697      0.832     0.776          **0.886**   0.795          0.843       [0.812]{.ul}
  H-2-Iab                     660           546    0.800       0.775      0.855     0.830          **0.858**   [0.847]{.ul}   0.824       0.807
                                                                                                                                          
  Average                                          0.785       0.711      0.849     0.763          **0.882**   [0.782]{.ul}   0.858       0.755
  WeightedAverage                                  0.784       0.709      0.843     0.762          **0.879**   [0.778]{.ul}   0.853       0.754

Each method contains results from all of the peptides (ALL) and the similarity reduced data (SR). The best-performing method for each allele in ALL dataset is marked by bold and the best performing method in SR dataset is underlined.

In case of class II peptides, MHC-PPM is the top performer by the average score in the Wang2008 dataset benchmark results. However, as can be seen in the Wang2010 dataset, NN-align \[[@B33]\] outperforms all other methods when included in the comparison. Nonetheless, even though MHC-PPM is designed only to find position independent rules, and there are no external steps for core region detection (or any information about the core region length), it still performs exceptionally well with an average AUC value of 0.858, slightly above SMM-align \[[@B31]\] (AUC of 0.849) and only \<0.03 lower than NN-align (AUC of 0.882).

Unlike what has been observed in class I molecules, class II molecules are believed to bind only to the core 9-mer region of a peptide. Although the core region occupies the peptide binding groove, the non-bound N- and C-terminus residues that lie outside the MHC anchor residues, called peptide flanking residues (PFRs), have been shown to affect the binding affinity and stability \[[@B11],[@B34]\]. NN-align and SMM-align use the length and composition of the peptide flanking residues in addition to the peptide binding core sequence. However, to keep the same length of the input throughout the data, the flanking residues are encoded in a summarized form, decreasing the information content. Due to nature of our algorithm, the differences in affinity due to the PFRs can be captured without losing any information. To test that hypothesis, we used experimental affinity values of 9 sequences which have the same core sequence and differ only in the flanking regions \[[@B11]\] and tried to predict the binding affinity values from the sequence (Table [4](#T4){ref-type="table"}). Although available data is limited, MHC-PPM has the lowest root mean squared error (RMSE). MHC-PPM also significantly outperforms ARB, SMM-align and NN-align in correlation of the predictions with the actual affinity values.

###### 

Effect of flanking peptides on the binding affinity to HLA DRB1\*1501 allele.

                      Experimental   ARB      NetMHCIIpan        SMM_align   NN_align   MHC-PPM
  ------------------- -------------- -------- ------------------ ----------- ---------- -------------------
  ENPVVHFFKNIVTPR     33             21.9     10                 21          8          11
  VVHFFKNIVHAAA       33             21.9     9.2                52          10.7       139
  VVHFFKNIVTAAA       45             21.9     9.5                20          11.5       224
  VVHFFKNIVT**K**AA   35             21.9     8.1                20          10.5       142
  VVHFFKNIVTA**K**A   4              21.9     8.1                20          9.8        83
  VVHFFKNIVTAA**K**   5              21.9     8.9                20          11.1       263
  **D**AVVHFFKNITVA   326            82.5     23.6               25          23.8       316
  A**D**VVHFFKNITVA   454            82.5     23.8               25          23.9       320
  AA**D**VHFFKNITVA   264            1286.7   45                 30          74.4       392
                                                                                        
  RMSE                               371.90   190.78             191.84      187.13     **[134.35]{.ul}**
  Pearson\'s Corr.                   0.349    **[0.728]{.ul}**   0.041       0.540      0.721

Experimental affinity measurements are from \[[@B11]\]. Predictions of other values calculated from the IEDB website\[[@B21]\]. MHC-PPM has the lowest root mean squared error (RMSE) and has a correlation score approximately equal to the top performing method.

Discussions
===========

In this study we present a position independent motif mining method representing amino acid sequences as time series data to predict peptides binding to MHC class I and class II proteins.

In class I MHC-peptide complexes, peptides have been observed to bulge out of the binding groove \[[@B5],[@B6]\], shifting the peptide side chains in the binding pockets. The main shortcoming of the existing prediction methods is their dependence on fixed length motifs, even though peptides of various lengths are known to bind to class I molecules \[[@B7]\]. Although a separate predictor can be created by applying the same method on a dataset of peptides of a different length, there is usually not enough available data for uncommon sequence lengths. There have been methods that use random sampling of insertions and deletions to fit the peptide into the 9-length window for prediction \[[@B35]\], however the fixed length limitation still present in the core.

For MHC class I predictions, MHC-PPM has been shown to slightly outperform other methods on the average. However, all methods have very close scores and perform equally well. Our main advantage is the ability to use peptides of any length during both training and prediction phases. While the curated benchmark dataset contains only 9-mers and 10-mers for the given alleles, we expect MHC-PPM to fare better in a more diverse dataset.

Commonly used prediction servers give the consensus prediction of different algorithms. The addition of our predictions into a consensus-decision step with other state-of-the-art algorithms will almost certainly benefit the end-users; the overall accuracy for the 9-mers will increase, and longer peptides that would have been previously ignored (or treated as 9-mers) will also be evaluated.

On MHC class II molecules, MHC-PPM was the top performing one in Wang2008 dataset by average AUC and just below NN-align in Wang2010 dataset. Even though NN-align outperforms all other methods including ours, the difference in performance values are not as drastic. Due to the fixed size core region, length independence is not much of an issue during score calculation. On the other hand, the position independence allows the inherent detection of the core region and allows better representation of the peptide flanking residues. During the prediction of the effects of PFRs on binding affinity (Table [4](#T4){ref-type="table"}), MHC-PPM resulted in the highest agreement with the experimental data, though more data is required for conclusive results.

On the subject of peptides binding to MHC class II molecules, the current view is that the peptides lie on a shallow groove with multiple contacts along the entire length of the peptide binding groove \[[@B9],[@B36]\]. This view does not address the possibility of peptides bulging out from the groove. There have been studies that proposed examples of peptide bulging (i.e. core binding region longer than 9 amino acids) in class II molecules for several alleles \[[@B9],[@B37]-[@B39]\]. Even though it is not known whether this is a general phenomenon for all class II alleles, it is possible that certain alleles can anchor peptides sufficiently at their N- and C-terminals to allow bulges, similar to class I molecules. If that is the case, a length insensitive method is required to correctly identify such examples, since NN-align and other methods require a fixed length core sequence.

The strength of MHC-PPM is its ability to capture length independent short motifs that are in close vicinity. Because the motif mining and prediction steps are uncoupled, the method can be used for different purposes. We have shown that the rules mined from the data can be used in conjunction with support vector machines or neural networks for non-linear prediction of any label (or quantitative value) that is correlated with the sequence motifs. However, the actual output of the algorithm is a collection of human-understandable rules and those motifs can be used as templates during sequence analysis or synthesis. Other than MHC binding predictions, the MHC-PPM method can also be applied to find motifs in gapped sequences, such as TCR recognition or receptor-ligand prediction problems. It is straightforward to extend the method to mine multiple groups of short sequence motifs (separated by relatively long distances) which co-occur frequently. We believe this approach can help uncover previously overlooked subtle sequence motifs in any large scale data.
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###### Additional File 1

**The candidate and frequent itemsets of all lengths for the given example sequences in Figure**[1](#F1){ref-type="fig"}, **for minimum support value of 0.4**. Red/bold values represent rules above the support threshold. At each step a candidate set C~k~is generated by extending the last frequent itemset L~k-1~, then the candidates are filtered according to the support values to generate the frequent itemset L~k~. This process is repeated until no frequent itemsets of a certain size can be found. Afterwards, the resulting frequent sets of different sizes (except L~1~) are merged together and filtered according to a given minimum confidence boundary.

###### 

Click here for file
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